Fig. 1: Cellular profiling of HER2 TKIs.
From: Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors
Profiling of Neratinib (a), Lapatinib (b), and Tucatinib (c) across a panel of 115 cancer cell lines encompassing 25 different cancer types. Cancer types are ranked from most to least sensitive to Neratinib by 10logIC50 values. Black dotted line indicates 1 µM.
